Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,930 GBX | +0.89% | +6.16% | +7.88% |
04-26 | HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets | |
04-25 | Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024 | CI |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.88% | 5.29B | B+ | ||
+25.92% | 661B | C+ | ||
+26.74% | 566B | B | ||
-6.78% | 352B | C+ | ||
+19.10% | 332B | B- | ||
+3.16% | 283B | C+ | ||
+13.43% | 231B | B+ | ||
+4.71% | 200B | B- | ||
-9.53% | 195B | A+ | ||
-4.39% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HIK Stock
- Ratings Hikma Pharmaceuticals PLC